Premium Nahrungsergänzungsmittel | artgerecht

Palexia – Uses, Dosage & Side Effects

Palexia is a prescription-only analgesic containing the active ingredient tapentadol. It is used to treat moderate to severe chronic pain.

Regular tips about health Regular tips about health

Things worth knowing about "Palexia"

Palexia is a prescription-only analgesic containing the active ingredient tapentadol. It is used to treat moderate to severe chronic pain.

What is Palexia?

Palexia is a prescription-only medication containing the active ingredient tapentadol. It belongs to the class of strong analgesics known as opioid analgesics and is used to treat moderate to severe pain that cannot be adequately controlled by other pain medications. Palexia is available in two formulations: Palexia (immediate-release) for acute pain episodes and Palexia SR (extended-release tablets) for the long-term management of chronic pain conditions.

Indications – When is Palexia Used?

Palexia is indicated for a range of pain conditions, including:

Chronic back pain and spinal disorders
Neuropathic pain (e.g. diabetic peripheral neuropathy)
Cancer-related pain in the context of palliative care
Postoperative pain when weaker analgesics are insufficient
Severe joint pain associated with osteoarthritis or rheumatic conditions

Mechanism of Action

Tapentadol, the active ingredient in Palexia, works through two complementary mechanisms:

Mu-opioid receptor agonism (MOR): Tapentadol binds to mu-opioid receptors in the brain and spinal cord, inhibiting the transmission of pain signals along the nervous system.
Norepinephrine reuptake inhibition (NRI): Tapentadol also inhibits the reuptake of norepinephrine in nerve cells, thereby enhancing the body's descending pain modulation pathways. This is particularly effective for neuropathic pain.

This dual mechanism, known as the MOR-NRI mechanism, distinguishes tapentadol from classical opioids such as morphine and allows for effective pain relief with a potentially improved tolerability profile, particularly with regard to gastrointestinal side effects.

Dosage and Administration

The dosage of Palexia is determined by pain intensity, individual patient response, and the formulation used:

Palexia (immediate-release): Taken every 4–6 hours; typical single dose of 50–100 mg
Palexia SR (extended-release): Taken twice daily approximately 12 hours apart; typical daily dose of 100–500 mg

Tablets should be swallowed whole with water. Palexia SR tablets must not be split, crushed, or chewed, as this may lead to uncontrolled release of the active substance and increase the risk of overdose. Dosage is always individually determined and adjusted by the treating physician.

Side Effects

Like all opioid analgesics, Palexia may cause side effects. The most common include:

Very common (> 10%): Nausea, dizziness, headache, drowsiness, vomiting
Common (1–10%): Constipation, decreased appetite, anxiety, sleep disturbances, dry mouth, sweating
Rare: Respiratory depression (slowed breathing), physical dependence with long-term use, serotonin syndrome (particularly when combined with other serotonergic substances)

Compared to classical opioids such as morphine or oxycodone, tapentadol tends to cause fewer gastrointestinal side effects such as constipation and nausea, which may improve patient adherence to treatment.

Contraindications and Interactions

Palexia must not be used in patients with:

Severe respiratory depression or severe asthma
Concomitant use of MAO inhibitors (e.g. tranylcypromine) or within 14 days of discontinuing them
Severe hepatic or renal impairment
Known hypersensitivity to tapentadol
Children and adolescents under 18 years of age

Important interactions exist with other centrally depressant substances (e.g. alcohol, benzodiazepines, other opioids) and with serotonergic medications (e.g. SSRIs, SNRIs), which may increase the risk of serotonin syndrome.

Dependence and Misuse

As an opioid analgesic, Palexia is subject to controlled substance regulations in most countries. There is a potential for physical and psychological dependence, as well as misuse. Treatment should therefore only be carried out under medical supervision, and discontinuation should always be done gradually and according to medical guidance in order to avoid withdrawal symptoms.

References

Palexia SR Summary of Product Characteristics, Grünenthal GmbH, current version (available via the European Medicines Agency database).
Kress HG et al. - Tapentadol in the management of chronic nociceptive and neuropathic pain: a comprehensive review. CNS Drugs, 2020; 34(11):1147-1176. PubMed PMID: 33034038.
World Health Organization (WHO) - WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. Geneva, 2018.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.